Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Asian Currencies Slip as Dollar Strengthens; Indian Rupee Rebounds on Intervention Hopes
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 



